Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 2062-2071

  Dienstmann, Rodrigo ^a   Serpico, Danila ^a   Rodon, Jordi ^a   Saura, Cristina ^a   Macarulla, Teresa ^a   Elez, Elena ^a   Alsina, Maria ^a   Capdevila, Jaume ^a   Perez Garcia, Jose ^a   Sánchez Ollé, Gessamí ^a   Aura, Claudia ^a   Prudkin, Ludmila ^a   Landolfi, Stefania ^a   Hernández Losa, Javier ^a   Vivancos, Ana ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPATOCYTE GROWTH FACTOR MONOCLONAL ANTIBODY; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOLECULAR DYNAMICS; MOLECULAR GENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHOSPHATIDYLINOSITOL 3 KINASE GENE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE I AS TOPIC; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION, MISSENSE; NEOPLASM METASTASIS; PATIENT SELECTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; TREATMENT OUTCOME;

EID: 84866070768     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0290     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 2011;17:114-26.
3. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS and PI3KCA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:756-62.
4. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139-45. (Pubitemid 47587019)
5. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009;27:2622-29.
6. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009;4:e7287.
7. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011;6:e22769.
8. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular coexpression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28. (Pubitemid 46330555)
9. Long IS, Han K, Li M, Shirasawa S, Sasazuki T, Johnston M, et al. Met receptor over-expression and oncogenic Ki-ras mutation cooperate to enhance the tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 2003;1:393-401. (Pubitemid 36437925)
10. Seiden-Long IM, Brown KR, Shihn W, Wigle DA, Radulovich N, Jurisica I, et al. Transcriptional targets of hepatocyte growth factor signaling and K-ras oncogene activation in colorectal cancer. Oncogene 2006;25:91-102. (Pubitemid 43050007)
11. Krumbach R, Schüler J, Hofman M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumor xenograft models: activation of MET as one mechanism of drug resistance. Eur J Cancer 2011;47:1231-43.
12. Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010;127:1941-7.
13. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
14. Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic signi ficance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956-68.
15. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
16. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 2011;10:2426-36.
17. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
18. Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res 2011;17:6052-60.
19. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
20. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 2009;4:e5717.
21. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.
22. Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012;72:779-89.
23. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
24. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505).
25. Catenacci DVT, Henderson L, Xiao S-Y, Patel P, Yauch RL, Hegde P, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011;1:573-9.
26. Rodón J, Saura C, Dienstmann R, Vivancos A, Cajal SR, Baselga J, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol 2012;9:359-66.
27. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010;28:4877-83.
28. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, et al. Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center initiative. J Clin Oncol 29: 2011 (suppl; abstr CRC2500).
29. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006;48:787-94. (Pubitemid 43800937)
30. Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, et al. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer 2011;105:814-23.
31. Angulo B, García-García E, Martínez R, Suárez-Gauthier A, Conde E, Hidalgo M, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010;12:292-9.
32. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904. (Pubitemid 40300298)
33. Janku F, Wheler JJ, Westing SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
34. Gasparini G, Longo R. The paradigm of personalized therapy in oncology. Expert Opin Ther Targets 2012;16 Suppl 1:S7-16.
35. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009;8:1352-8.
36. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009;69:143-50.
37. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010;120:2858-66.
38. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011;6:e25132.
39. Bhagwat SV, Gkhale PC, Crew AP, Cooke A, Yao Y, Mantis C, et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 2011;10:1394-406.
40. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
41. Mallon R, Feldberg LR, Lucas J, Chaudhary I, Dehnhardt C, Santos ED, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor. Clin Cancer Res 2011;17:3193-203.
42. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
43. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco D, Smith LS, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25.
44. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28: 2010 (suppl; abstr 3534).
45. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
46. Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell EP, et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab(pmab) versus pmab alone in patients with wild-type KRAS metastatic colorectal cancer. J Clin Oncol 29: 2011 (suppl; abstr 3500).
47. Bessudo A, Bendell JC, Gabrail N, Kopp MV, Mueller L, Hart LL, et al. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan, and cetuximab in patients with wild-type KRAS metastatic colorectal cancer who have received front-line systemic therapy. J Clin Oncol 29: 2011 (suppl; abstr 3582).